Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Peposertib and Liposomal Doxorubicin in Advanced Soft Tissue Sarcomas
NCT05711615Phase 1Recruiting
- Sponsor
- National Cancer Institute
- Start
- Feb 2024
- Primary completion
- May 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of peposertib in soft tissue sarcoma (STS), sponsored by National Cancer Institute. Primary endpoint: Dose limiting toxicity rate at 28 days. Started Feb 2024; status: recruiting.
02
Drugs
peposertib
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on NCT05711615.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05711615.